Vertex Pharmaceuticals (VRTX) Other financing activities (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Other financing activities of -$400000.0 for Q1 2026, down 102.4% year-over-year from $16.7 million in Q1 2025, and down 136.36% quarter-over-quarter from $1.1 million in Q4 2025.
Vertex Pharmaceuticals (VRTX) Other financing activities (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Other financing activities history runs 18 years deep, the most recent figure standing at -$400000.0 for Q1 2026.
- In Q1 2026, Other financing activities fell 102.4% year-over-year to -$400000.0; the TTM figure through Mar 2026 stood at -$13.4 million (down 111.71% YoY), while the FY2025 annual figure was $3.7 million, down 96.77% from the prior year.
- Other financing activities for Q1 2026 stood at -$400000.0, down from $1.1 million in the prior quarter.
- The five-year high for Other financing activities was $109.3 million in Q4 2024, with the low at -$131.2 million in Q4 2022.
- The 5-year median for Other financing activities is $1.1 million (2023), against an average of $7.2 million.
- The sharpest annual moves came in 2023 and 2024: Other financing activities tumbled 289.89% in 2023, then jumped 7386.67% in 2024.
- Vertex Pharmaceuticals' Other financing activities stood at -$131.2 million in 2022, then surged by 98.86% to -$1.5 million in 2023, then surged by 7386.67% to $109.3 million in 2024, then plunged by 98.99% to $1.1 million in 2025, then sank by 136.36% to -$400000.0 in 2026.
- Business Quant data shows VRTX's Other financing activities at -$400000.0 in Q1 2026, $1.1 million in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 47.70 Mn |
| Jun 30, 2026 | 47.70 Mn |
| Mar 31, 2026 | -400,000.00 |
| Mar 31, 2026 | -400,000.00 |
| Dec 31, 2025 | 1.10 Mn |
| Dec 31, 2025 | 1.10 Mn |
| Sep 30, 2025 | 1.10 Mn |
| Sep 30, 2025 | 1.10 Mn |
| Jun 30, 2025 | -15.20 Mn |
| Jun 30, 2025 | -15.20 Mn |
| Mar 31, 2025 | 16.70 Mn |
| Mar 31, 2025 | 16.70 Mn |
| Dec 31, 2024 | 109.30 Mn |
| Dec 31, 2024 | 109.30 Mn |
| Sep 30, 2024 | 900,000.00 |
| Sep 30, 2024 | 900,000.00 |
| Jun 30, 2024 | -12.50 Mn |
| Jun 30, 2024 | -12.50 Mn |
| Mar 31, 2024 | 16.90 Mn |
| Mar 31, 2024 | 16.90 Mn |